Provectus Biopharmaceuticals (PVCT) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	800 S Gay Street
Entity Address, Address Line Two	Suite 1610
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37929
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		419,497,119

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 84,274	$ 682,984
Restricted cash	1,948,335	2,423,958
Short-term receivables	2,744	5,107
Prepaid expenses and other current assets	243,394	329,908
Total Current Assets	2,278,747	3,441,957
Equipment and furnishings, less accumulated depreciation of $97,215 and $91,178, respectively	25,799	31,836
Operating lease right-of-use asset	138,863	39,563
Total Assets	2,443,409	3,513,356
Current Liabilities:
Accounts payable	1,894,201	1,287,459
Deposit for purchase of Series D-1 Preferred Stock		150,000
Unearned grant revenue	1,990,685	2,500,000
Other accrued expenses	2,331,621	2,002,486
Accrued interest	68,389	10,578
Accrued interest - related parties	14,044	6,044
Notes payable	142,693	238,452
Convertible notes payable	1,810,000	1,260,000
Convertible notes payable - related parties	200,000	200,000
Operating lease liability, current portion	42,662	45,617
Total Current Liabilities	8,494,295	7,700,636
Operating lease liability, non-current portion	96,201
Total Liabilities	8,590,496	7,700,636
Commitments, contingencies, and litigations (Note 11)
Stockholders’ Deficiency:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,447,119 shares issued and outstanding at June 30, 2022 and December 31, 2021	419,447	419,447
Additional paid-in capital	241,590,054	241,440,106
Accumulated other comprehensive loss	(35,511)	(34,467)
Accumulated deficit	(248,142,721)	(246,033,958)
Total Stockholders’ Deficiency	(6,147,087)	(4,187,280)
Total Liabilities and Stockholders’ Deficiency	2,443,409	3,513,356
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock, value	12,373	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock, value	$ 9,271	$ 9,219

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 97,215	$ 91,178
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Outstanding	419,447,119	419,447,119
Common shares, Issued	419,447,119	419,447,119
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	12,374,000	12,374,000
Preferred stock, shares issued	12,373,247	12,373,247
Preferred stock, shares outstanding	12,373,247	12,373,247
Preferred stock, liquidation preference per share	$ 14,164,889	$ 14,164,889
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	11,241,000	11,241,000
Preferred stock, shares issued	9,270,860	9,218,449
Preferred stock, shares outstanding	9,270,860	9,218,449
Preferred stock, liquidation preference per share	$ 106,132,320	$ 105,532,804

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Grant Revenue	$ 321,710		$ 509,315
Operating Expenses:
Research and development	816,648	602,979	1,487,764	1,258,123
General and administrative	583,042	619,038	1,099,589	1,144,570
Total Operating Expenses	1,399,690	1,222,017	2,587,353	2,402,693
Total Operating Loss	(1,077,980)	(1,222,017)	(2,078,038)	(2,402,693)
Other Income/(Expense):
Research and development tax credit	38,259	32,144	38,259	32,144
Gain from extinguishment		63,094		63,094
Interest income and interest expense	(38,120)	(452,812)	(68,984)	(942,086)
Total Other Income/(Expense), Net	139	(357,574)	(30,725)	(846,848)
Net Loss	$ (1,077,841)	$ (1,579,591)	$ (2,108,763)	$ (3,249,541)
Basic and Diluted Loss Per Common Share	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	419,447,119	403,628,466	419,447,119	402,910,628

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net Loss	$ (1,077,841)	$ (1,579,591)	$ (2,108,763)	$ (3,249,541)
Other Comprehensive Loss:
Foreign currency translation adjustments	(328)	(1,121)	(1,044)	(284)
Total Comprehensive Loss	$ (1,078,169)	$ (1,580,712)	$ (2,109,807)	$ (3,249,825)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Beginning balance, value	$ (5,068,918)	$ (4,187,280)	$ (31,615,870)	$ (30,206,357)	$ (4,187,280)	$ (30,206,357)
Common stock issued upon exercise of warrants			10,660	239,850
Common stock			1,675	19,750
Warrants			488
Conversion of PRH Notes to Series D Preferred Stock			3,541,222
Conversion of PRH Notes to Series D-1 Preferred Stock			27,031,858
Series D-1 Preferred Stock issued for cash		150,000
Net income (loss)	(1,077,841)	(1,030,922)	(1,579,591)	(1,669,950)	(2,108,763)	(3,249,541)
Other comprehensive income (loss)	(328)	(716)	(1,121)	837
Balance at June 30, 2021	(6,147,087)	(5,068,918)	(2,610,682)	(31,615,870)	(6,147,087)	(2,610,682)
Series D-1 Convertible Preferred Stock [Member]
Series D-1 Preferred Stock issued for cash					$ 150,000
Series D-1 Preferred Stock issued for cash, shares					52,411
Preferred Stock [Member] | Series B Preferred Stock [Member]
Beginning balance, value
Beginning balance, shares			100	100		100
Common stock issued upon exercise of warrants
Common stock
Warrants
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Net income (loss)
Other comprehensive income (loss)
Balance at June 30, 2021
Ending balance, shares			100	100		100
Preferred Stock [Member] | Series D Convertible Preferred Stock [Member]
Beginning balance, value	$ 12,373	$ 12,373			$ 12,373
Beginning balance, shares	12,373,247	12,373,247			12,373,247
Common stock issued upon exercise of warrants
Common stock
Warrants
Conversion of PRH Notes to Series D Preferred Stock			$ 12,373
Conversion of PRH Notes to Series D Preferred Stock, shares			12,373,247
Conversion of PRH Notes to Series D-1 Preferred Stock
Series D-1 Preferred Stock issued for cash
Net income (loss)
Other comprehensive income (loss)
Balance at June 30, 2021	$ 12,373	$ 12,373	$ 12,373		$ 12,373	$ 12,373
Ending balance, shares	12,373,247	12,373,247	12,373,247		12,373,247	12,373,247
Preferred Stock [Member] | Series D-1 Convertible Preferred Stock [Member]
Beginning balance, value	$ 9,271	$ 9,219			$ 9,219
Beginning balance, shares	9,270,860	9,218,449			9,218,449
Common stock issued upon exercise of warrants
Common stock
Warrants
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock			$ 9,441
Conversion of PRH Notes to Series D-1 Preferred Stock, shares			9,440,594
Series D-1 Preferred Stock issued for cash		$ 52
Series D-1 Preferred Stock issued for cash, shares		52,411
Net income (loss)
Other comprehensive income (loss)
Balance at June 30, 2021	$ 9,271	$ 9,271	$ 9,441		$ 9,271	$ 9,441
Ending balance, shares	9,270,860	9,270,860	9,440,594		9,270,860	9,440,594
Common Stock [Member]
Beginning balance, value	$ 419,447	$ 419,447	$ 403,558	$ 398,808	$ 419,447	$ 398,808
Beginning balance, shares	419,447,119	419,447,119	403,557,037	398,807,037	419,447,119	398,807,037
Common stock issued upon exercise of warrants			$ 200	$ 4,500
Common stock issued upon exercise of warrants, shares			200,000	4,500,000
Common stock			$ 25	$ 250
Common stock, shares			25,000	250,000
Warrants
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Series D-1 Preferred Stock issued for cash
Net income (loss)
Other comprehensive income (loss)
Balance at June 30, 2021	$ 419,447	$ 419,447	$ 403,783	$ 403,558	$ 419,447	$ 403,783
Ending balance, shares	419,447,119	419,447,119	403,782,037	403,557,037	419,447,119	403,782,037
Additional Paid-in Capital [Member]
Beginning balance, value	$ 241,590,054	$ 241,440,106	$ 210,178,197	$ 209,923,347	$ 241,440,106	$ 209,923,347
Common stock issued upon exercise of warrants			10,460	235,350
Common stock			1,650	19,500
Warrants			488
Conversion of PRH Notes to Series D Preferred Stock			3,528,849
Conversion of PRH Notes to Series D-1 Preferred Stock			27,022,417
Series D-1 Preferred Stock issued for cash		149,948
Net income (loss)
Other comprehensive income (loss)
Balance at June 30, 2021	241,590,054	241,590,054	240,742,061	210,178,197	241,590,054	240,742,061
AOCI Attributable to Parent [Member]
Beginning balance, value	(35,183)	(34,467)	(33,260)	(34,097)	(34,467)	(34,097)
Common stock issued upon exercise of warrants
Common stock
Warrants
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Series D-1 Preferred Stock issued for cash
Net income (loss)
Other comprehensive income (loss)	(328)	(716)	(1,121)	837
Balance at June 30, 2021	(35,511)	(35,183)	(34,381)	(33,260)	(35,511)	(34,381)
Retained Earnings [Member]
Beginning balance, value	(247,064,880)	(246,033,958)	(242,164,365)	(240,494,415)	(246,033,958)	(240,494,415)
Common stock issued upon exercise of warrants
Common stock
Warrants
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Series D-1 Preferred Stock issued for cash
Net income (loss)	(1,077,841)	(1,030,922)	(1,579,591)	(1,669,950)
Other comprehensive income (loss)
Balance at June 30, 2021	$ (248,142,721)	$ (247,064,880)	$ (243,743,959)	$ (242,164,365)	$ (248,142,721)	$ (243,743,959)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows From Operating Activities:
Net loss	$ (2,108,763)	$ (3,249,541)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		21,913
Non-cash lease expense	31,142	40,012
Depreciation	6,037	6,432
Gain on forgiveness of PPP Loan and interest		(63,094)
Changes in operating assets and liabilities
Short term receivables	2,363	(1,632)
Prepaid expenses and other current assets	143,940	123,230
Accounts payable - trade	606,742	252,254
Unearned grant revenue	(509,315)
Other accrued expenses	329,135	152,786
Operating lease liability	(37,196)	(42,191)
Accrued interest expense	65,811	940,212
Net Cash Used In Operating Activities	(1,470,104)	(1,819,619)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	550,000	1,700,000
Repayment of short-term note payable	(153,185)	(95,387)
Note Payable		(85,398)
Proceeds from exercise of warrants		250,510
Net Cash Provided By Financing Activities	396,815	1,769,725
Effect of exchange rates on cash, cash equivalents, and restricted cash	(1,044)	70
Net Decrease In Cash, Cash Equivalents, and Restricted Cash	(1,074,333)	(49,824)
Cash, Cash Equivalents, and Restricted Cash, Beginning of Period	3,106,942	97,231
Cash, Cash Equivalents, and Restricted Cash, End of Period	2,032,609	47,407
Cash and cash equivalents	84,274	47,407
Restricted cash	1,948,335
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Purchase of insurance policies financed by short-term note payable	(57,426)	(309,710)
Deposit applied for purchase of Series D-1 Preferred Stock	(150,000)
Conversion of non-amended 2017 Notes to Series D Preferred Stock		3,541,222
Conversion of amended 2017 Notes and 2020 Notes to Series D-1 Preferred Stock		27,031,858
Right-of-use assets obtained in exchange for operating lease liabilities	$ 130,422

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of small molecules called halogenated xanthenes (“HXs”), a class entirely owned by the Company. Our lead HX molecule is named rose bengal sodium (“RBS”). The Company has established a multi-step approach using quality-by-design principles for synthesizing and manufacturing pharmaceutical-grade RBS by current good manufacturing practice (“cGMP”) and under the guidelines of The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. A second HX molecule has been synthesized, 4,5,6,7-tetrabromo-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenz- ofuran-1,9′-xanthen]-3-one. ● Oncology: ® Oral formulations of cGMP RBS are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers. ● Pediatric Oncology: ● Hematology: ● Virology: ● Microbiology: ● Ophthalmology: ● Dermatology: ® ● Animal Health: To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. SARS-CoV-2 was first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at June 30, 2022. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash, cash equivalents, and restricted cash were $ 2,032,609 1,948,335 6,215,548 4,258,679 The Company plans to access capital resources through possible public or private equity offerings, including the 2021 financing (see Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2022 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Since the date the Company’s December 31, 2021 consolidated financial statements were issued in its 2021 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below. Recently Adopted Accounting Standards In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company’s cash equivalents consist of Treasury bills of $ 0 42,594 Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 551,665 Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 1,782,609 2,856,942 Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, June 30, 2022 2021 Warrants 512,500 82,589,164 Options 3,425,000 4,800,000 Convertible preferred stock 105,081,847 106,778,757 2021 unsecured convertible notes 7,311,088 - Total potentially dilutive shares 116,330,435 194,167,921

Other Accrued Expenses

Other Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at June 30, 2022 and December 31, 2021: Schedule of Other Accrued Expenses June 30, 2022 December 31, 2021 Accrued payroll and taxes $ 259,008 $ 174,533 Accrued vacation 56,356 42,871 Accrued directors’ fees 1,753,089 1,560,589 Accrued other expenses 263,168 224,493 Total Other Accrued Expenses $ 2,331,621 $ 2,002,486

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable 2021 Financing Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ 1,260,000 $ 200,000 $ 1,460,000 Issued 50,000 - 50,000 Balance as of March 31, 2022 $ 1,310,000 $ 200,000 $ 1,510,000 Beginning Balance $ 1,310,000 $ 200,000 $ 1,510,000 Issued 500,000 - 500,000 Balance as of June 30, 2022 $ 1,810,000 $ 200,000 $ 2,010,000 Ending Balance $ 1,810,000 $ 200,000 $ 2,010,000 For further details on the terms of the 2021 Notes, refer to our Form 10-K as filed with the SEC on March 29, 2022. As of June 30, 2022, the Company had received 2021 Notes proceeds of $ 2,010,000 200,000 Subsequent to June 30, 2022, the Company received 2021 Notes proceeds of $ 225,000

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of June 30, 2022 and December 31, 2021, the balance of the note payable was $ 142,693 238,452

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During the three months ended June 30, 2022 and 2021, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 42,400 42,400 18,750 18,750 During the six months ended June 30, 2022 and 2021, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 84,800 127,200 37,500 37,500 Accrued director fees for Mr. Horowitz as of June 30, 2022 and December 31, 2021 were $ 318,750 281,250 169,600 127,200 See Note 5 for details of other related party transactions. Director fees during the three months ended June 30, 2022 and 2021 were $ 96,250 96,250 192,500 192,500 1,753,089 1,560,589

Stockholders_ Deficiency

Stockholders’ Deficiency	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders’ Deficiency	8. Stockholders’ Deficiency Preferred Stock During the six months ended June 30, 2022, the Company issued 52,411 150,000 Annual Stockholder Meeting Proposals The Company held its annual meeting of stockholders on June 22, 2022. As proposal number 4, stockholders authorized the Company’s board of directors (the “Board”) to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases
Leases	9. Leases The Company leased 4,500 five years 6,100 On June 30, 2022, the lease expired and was not renewed. On June 18, 2022, the Company moved into 2,700 three years 4,053 4,278 Total operating lease expense for the three months ended June 30, 2022 was $ 23,092 15,395 7,697 23,044 15,363 7,681 Total operating lease expense for the six months ended June 30, 2022 was $ 38,051 25,367 12,684 47,806 31,871 15,935 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Six Months Ended June 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 38,625 $ 45,784 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 151,693 $ - Weighted Average Remaining Lease Term Operating leases 3 years 1 year Weighted Average Discount Rate Operating leases 5% 8.0 % 8.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2022 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 $ 24,318 2023 49,311 2024 50,663 2025 25,669 Total future minimum lease payments 149,961 Less: amount representing imputed interest 11,098 Total $ 138,863

Grants

Grants	6 Months Ended
	Jun. 30, 2022
Grants
Grants	10. Grants On October 25, 2021, the Company received a grant award of $ 2,500,000 1,990,685 509,315

Commitments, Contingencies and

Commitments, Contingencies and Litigation	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	11. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising from the ordinary course of business and/or that may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Convertible Notes Payable Subsequent to June 30, 2022, the Company received 2021 Notes proceeds of $ 225,000 Common Stock Subsequent to June 30, 2022, the Company issued an aggregate of 25,000 1,500 Subsequent to June 30, 2022, the Company issued an aggregate of 25,000 1,500

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company’s cash equivalents consist of Treasury bills of $ 0 42,594
Restricted Cash	Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 551,665
Cash Concentrations	Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 1,782,609 2,856,942
Reclassifications	Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, June 30, 2022 2021 Warrants 512,500 82,589,164 Options 3,425,000 4,800,000 Convertible preferred stock 105,081,847 106,778,757 2021 unsecured convertible notes 7,311,088 - Total potentially dilutive shares 116,330,435 194,167,921

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, June 30, 2022 2021 Warrants 512,500 82,589,164 Options 3,425,000 4,800,000 Convertible preferred stock 105,081,847 106,778,757 2021 unsecured convertible notes 7,311,088 - Total potentially dilutive shares 116,330,435 194,167,921

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at June 30, 2022 and December 31, 2021: Schedule of Other Accrued Expenses June 30, 2022 December 31, 2021 Accrued payroll and taxes $ 259,008 $ 174,533 Accrued vacation 56,356 42,871 Accrued directors’ fees 1,753,089 1,560,589 Accrued other expenses 263,168 224,493 Total Other Accrued Expenses $ 2,331,621 $ 2,002,486

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ 1,260,000 $ 200,000 $ 1,460,000 Issued 50,000 - 50,000 Balance as of March 31, 2022 $ 1,310,000 $ 200,000 $ 1,510,000 Beginning Balance $ 1,310,000 $ 200,000 $ 1,510,000 Issued 500,000 - 500,000 Balance as of June 30, 2022 $ 1,810,000 $ 200,000 $ 2,010,000 Ending Balance $ 1,810,000 $ 200,000 $ 2,010,000

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Six Months Ended June 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 38,625 $ 45,784 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 151,693 $ - Weighted Average Remaining Lease Term Operating leases 3 years 1 year Weighted Average Discount Rate Operating leases 5% 8.0 % 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2022 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 $ 24,318 2023 49,311 2024 50,663 2025 25,669 Total future minimum lease payments 149,961 Less: amount representing imputed interest 11,098 Total $ 138,863

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and restricted cash	$ 2,032,609	$ 3,106,942	$ 47,407	$ 97,231
Restricted cash	1,948,335
Working capital deficiency	$ 6,215,548	$ 4,258,679

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	116,330,435	194,167,921
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	512,500	82,589,164
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,425,000	4,800,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	105,081,847	106,778,757
2021 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	7,311,088

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	Oct. 25, 2021	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash equivalent - treasury bills		$ 0	$ 42,594
Proceeds from grant	$ 2,500,000
Payment to vendors for expense	$ 551,665
Insured limits		250,000
Cash in excess FDIC insured amount		$ 1,782,609	$ 2,856,942

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued payroll and taxes	$ 259,008	$ 174,533
Accrued vacation	56,356	42,871
Accrued directors’ fees	1,753,089	1,560,589
Accrued other expenses	263,168	224,493
Total Other Accrued Expenses	$ 2,331,621	$ 2,002,486

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021
Short-Term Debt [Line Items]
Issued			$ 3,541,222
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Beginning Balance	$ 1,510,000	$ 1,460,000
Issued	500,000	50,000
Ending Balance	2,010,000	1,510,000
Convertible Notes Payable [Member] | Non-Related Party [Member]
Short-Term Debt [Line Items]
Beginning Balance	1,310,000	1,260,000
Issued	500,000	50,000
Ending Balance	1,810,000	1,310,000
Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Beginning Balance	200,000	200,000
Issued
Ending Balance	$ 200,000	$ 200,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)		6 Months Ended
	Aug. 15, 2022	Jun. 30, 2022	Jun. 30, 2021
Short-Term Debt [Line Items]
Proceeds from note payable		$ 550,000	$ 1,700,000
2021 Note [Member] | Officer [Member]
Short-Term Debt [Line Items]
Proceeds from note payable		2,010,000
Proceeds from related party investor		$ 200,000
2021 Note [Member] | Directors [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Proceeds from note payable	$ 225,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Note payable	$ 142,693	$ 238,452

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Director fees	$ 96,250	$ 96,250	$ 192,500	$ 192,500
Accrued directors fees	1,753,089		1,753,089		$ 1,560,589
Mr Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Professional fees	42,400	42,400	84,800	127,200
Accrued directors fees	318,750		318,750		281,250
Mr Bruce Horowitz [Member] | Director [Member]
Related Party Transaction [Line Items]
Director fees	$ 18,750	$ 18,750	37,500	$ 37,500
Mr Bruce Horowitz [Member] | Director [Member] | Capital Strategists [Member]
Related Party Transaction [Line Items]
Professional fees			$ 169,600		$ 127,200

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Jun. 30, 2022
Class of Stock [Line Items]
Issuance of stock, value	$ 150,000
Reverse stock split		to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50
Series D-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Issuance of stock, shares		52,411
Issuance of stock, value		$ 150,000

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 38,625	$ 45,784
Right-of-use assets obtained in exchange for lease obligations: Operating leases	$ 151,693
Weighted Average Remaining Lease Term: Operating leases	3 years	1 year
Weighted Average Discount Rate: Operating leases		8%
Minimum [Member]
Weighted Average Discount Rate: Operating leases	5%
Maximum [Member]
Weighted Average Discount Rate: Operating leases	8%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Jun. 30, 2022 USD ($)
Leases
2022	$ 24,318
2023	49,311
2024	50,663
2025	25,669
Total future minimum lease payments	149,961
Less: amount representing imputed interest	11,098
Total	$ 138,863

Leases (Details Narrative)

Leases (Details Narrative)		3 Months Ended		6 Months Ended
	Jun. 18, 2022 USD ($) ft²	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)
Research and Development Expense [Member]
Operating lease, expense		$ 15,395	$ 15,363	$ 25,367	$ 31,871
General and Administrative Expense [Member]
Operating lease, expense		7,697	7,681	12,684	15,935
Property Subject to Operating Lease [Member]
Operating lease, expense		$ 23,092	$ 23,044	$ 38,051	$ 47,806
Knoxville, Tennessee [Member]
Area of land | ft²	2,700	4,500		4,500
Lessee, operating lease, term of contract	3 years	5 years		5 years
Rent expenses per month				$ 6,100
Knoxville, Tennessee [Member] | Minimum [Member]
Rent expenses per month	$ 4,053
Knoxville, Tennessee [Member] | Maximum [Member]
Rent expenses per month	$ 4,278

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Oct. 25, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Grants
Proceeds from grant award for study of animal cancer and dermatological	$ 2,500,000
Unearned grant revenue liability		$ 1,990,685		$ 1,990,685		$ 2,500,000
Grant revenue		$ 321,710		$ 509,315

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		6 Months Ended
	Aug. 15, 2022	Jun. 30, 2022	Jun. 30, 2021
Subsequent Event [Line Items]
Proceeds from convertible debt		$ 550,000	$ 1,700,000
Consultant [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Issuance of stock for service, shares	25,000
Issuance of stock for service, value	$ 1,500
Employee [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Issuance of stock for service, shares	25,000
Issuance of stock for service, value	$ 1,500
2021 Note [Member] | Director [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from convertible debt	$ 225,000